Skip to main content

Table 2 Estimated OR/WMD and 95% CI from pairwise meta-analysis in terms of Blood loss, Transfusion risk, Change of Hb, DVT and PE

From: Hemostatic effect of tourniquet combined with tranexamic acid in total knee arthroplasty: a network meta-analysis

Included studies Comparisons Pairwise meta-analysis
WMD(95%CI) I2 Ph
The total blood loss
(PMID:29544472;PMID:29257010;PMID:27267228;PMID:27194493;PMID:26507526;PMID:27259391;PMID:27222617;PMID:26894222;PMID:12697586;PMID:11476309;PMID:10673876; PMID:8636182)
1 study IV vs. control −277.34 (−431.85–122.83) NA NA
1 study Topical vs. control −307.78 (−460.92–154.64) NA NA
1 study Topical vs. IV 30.44 (163.81–102.93) NA NA
2 studies IV + topical vs. IV −218.13 (−282.59–153.68) 46.8% 0.17
1 study Oral vs. topical 83.60 (203.84–36.64) NA NA
1 study T VS. IV + topical 956.60 (829.31–1083.89) NA NA
6 studies IV + T vs. T −156.09 (−179.41–132.78) 98.1% <0.01
2 studies Topical+T vs. T −79.20 (−106.34–52.05) 87.6% <0.01
3 studies Topical+T vs. IV + T 10.90 (7.95–29.72) 62.5% 0.07
1 study IV + topical+T vs. IV + topical 106.80 (13.04–200.56) NA NA
1 study IV + topical+T vs. T −849.80(−987.51–712.09) NA NA
Transfusion risk
(PMID:29544472;PMID:29257010;PMID:27267228;PMID:26507526;PMID:27222617;PMID:24816760;PMID:26894222;PMID:24768543;PMID:12697586;PMID:11476309;PMID:10673876)
1 study IV vs. control 0.23 (0.08–0.74) NA NA
1 study Topical vs. control 0.35 (0.13–1.00) NA NA
1 study Topical vs. IV 1.48 (0.43–5.14) NA NA
1 study IV + topical vs. IV 0.24 (0.03–2.23) NA NA
1 study Oral vs. topical 0.73 (0.16–3.38) NA NA
1 study T VS. IV + topical 20.20 (1.13–360.28) NA NA
5 studies IV + T vs. T 0.09 (0.04–0.17) 0% 0.77
3 studies Topical+T vs. T 0.19 (0.10–0.37) 46.2% 0.16
3 studies Topical+T vs. IV + T 0.99 (0.34–2.85) 0% 0.76
1 study IV + Topical+T vs. T 0.05 (0.00–0.88) NA NA
The change of Hb
(PMID:29544472;PMID:29257010;PMID:27267228;PMID:27194493;PMID:26507526;PMID:27259391;PMID:27222617;PMID:26894222;PMID:24768543;PMID:11476309)
1 study IV vs. control 1.17 (0.54–1.80) NA NA
1 study Topical vs. control 1.42 (0.78–2.06) NA NA
1 study Topical vs. IV 0.25 (0.32–0.82) NA NA
2 studies IV + topical vs. IV 0.67 (0.48–0.86) 0% 0.81
1 study Oral vs. topical 0.20 (0.13–0.53) NA NA
1 study T VS. IV + topical −1.61 (−1.90–1.32) NA NA
3 studies IV + T vs. T 2.50 (2.09–2.90) 94.8% <0.01
2 studies Topical+T vs. T 1.42 (0.84–2.00) 5.4% 0.30
4 studies Topical+T vs. IV + T 0.57 (0.31–0.84) 92.0% <0.01
1 study IV + topical+T vs. IV + topical −0.20 (−0.38–0.02) NA NA
1 study IV + topical+T vs. T 1.41 (1.11–1.71) NA NA
DVT
(PMID:29257010;PMID:27194493;PMID:26507526;PMID:27259391;PMID:24816760;PMID:26894222;PMID:24768543;PMID:12697586;PMID:10673876; PMID:8636182)
1 study IV + topical vs. IV 0.33 (0.01–8.35) NA NA
3 studies IV + T vs.T 0.80 (0.24–2.63) 0% 0.50
1 study Topical+T vs. IV + T 0.55 (0.05–6.21) NA NA
PE
(PMID:29257010;PMID:27194493;PMID:26507526;PMID:27259391;PMID:24816760;PMID:26894222;PMID:10673876;PMID:8636182)
1 study IV + topical vs. IV 0.33 (0.01–8.35) NA NA
2 studies IV + T vs. T 0.22 (0.24–2.14) 0% 0.83
1 study Topical+T vs. IV + T 0.55 (0.05–6.21) NA NA
  1. Notes: WMD weighted mean difference, 95%CI 95% confidence intervals, Hb hemoglobin, DVT deep vein thrombosis, PE pulmonary embolism, Control = placebo; IV=IV TXA; topical = topical TXA; IV + topical = IV-combined topical TXA; Oral = oral TXA; T = placebo+tourniquets; IV + T = IV TXA + tourniquets; Topical+T = topical TXA + tourniquets; IV + topical+T = IV-combined topical TXA + tourniquets